NEW YORK, - OSI Pharmaceuticals (OSIP.O) shares could benefit as the Melville, N.Y.-based company expands the uses of its lung-cancer drug, Barron's said.
OSI's sales of Tarceva, the second-largest oral anti-cancer drug, hit $1 billion last year.
OSI trades for about $32 a share, about 18 times next year's earnings, Barron's said, projecting it could rally to $45 a share in the coming year with the help of Tarceva.
No comments:
Post a Comment